Total Payments
$410.83
2021 Payments
$11.88
Companies
9
Transactions
26
Medicare Patients
3,860
Medicare Billing
$811,044
Payment Breakdown by Category
Food & Beverage$410.83 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $410.83 | 26 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $143.59 | 10 | $0 (2018) |
| Theravance Biopharma Inc. | $121.59 | 7 | $0 (2017) |
| ViiV Healthcare Company | $41.86 | 2 | $0 (2017) |
| Shire North American Group Inc | $25.75 | 2 | $0 (2017) |
| Gilead Sciences, Inc. | $20.27 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $18.03 | 1 | $0 (2017) |
| PFIZER INC. | $14.83 | 1 | $0 (2017) |
| Seqirus USA Inc | $13.03 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $11.88 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $11.88 | 1 | Janssen Biotech, Inc. ($11.88) |
| 2018 | $29.15 | 2 | Allergan Inc. ($29.15) |
| 2017 | $369.80 | 23 | Theravance Biopharma Inc. ($121.59) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 07/25/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/26/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/20/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/06/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/03/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/25/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/13/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Infectious Disease | ||||||
| 07/12/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/25/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Infectious Disease | ||||||
| 05/23/2017 | Seqirus USA Inc | Fluad (Biological) | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: Vaccine | ||||||
| 05/12/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $6.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/03/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Infectious Disease | ||||||
| 04/28/2017 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.27 | General |
| 04/26/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Infectious Disease | ||||||
| 04/04/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: Infectious Disease | ||||||
| 03/20/2017 | PFIZER INC. | PREVNAR - 13 (Biological), TRUMENBA | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: VACCINES | ||||||
| 03/16/2017 | Shire North American Group Inc | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: IMMUNOLOGY | ||||||
| 03/13/2017 | ViiV Healthcare Company | TRIUMEQ (Drug), TIVICAY | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: HIV | ||||||
| 03/09/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Infectious Disease | ||||||
| 02/04/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/02/2017 | ViiV Healthcare Company | TRIUMEQ (Drug), TIVICAY | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: HIV | ||||||
| 01/28/2017 | Shire North American Group Inc | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: IMMUNOLOGY | ||||||
| 01/26/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/10/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,347 | 9,266 | $930,769 | $325,780 |
| 2022 | 11 | 1,103 | 9,459 | $762,842 | $265,939 |
| 2021 | 9 | 712 | 1,286 | $318,220 | $109,276 |
| 2020 | 6 | 698 | 1,342 | $311,802 | $110,050 |
Total Patients
3,860
Total Services
21,353
Medicare Billing
$811,044
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 64 | 6,600 | $315,540 | $121,689 | 38.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 245 | 642 | $128,400 | $58,032 | 45.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 227 | 248 | $119,040 | $33,014 | 27.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 42 | 531 | $119,475 | $26,430 | 22.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 218 | 420 | $71,400 | $25,358 | 35.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Office | 2023 | 92 | 172 | $34,400 | $15,353 | 44.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Office | 2023 | 77 | 81 | $38,880 | $10,617 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 66 | $22,044 | $8,536 | 38.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 83 | 85 | $28,050 | $8,452 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 62 | $15,190 | $6,074 | 40.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Office | 2023 | 66 | 97 | $16,490 | $5,664 | 34.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 43 | 51 | $9,180 | $2,821 | 30.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Office | 2023 | 19 | 19 | $6,270 | $1,784 | 28.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 74 | 161 | $5,635 | $1,695 | 30.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 13 | 31 | $775.00 | $260.40 | 33.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 335 | 969 | $193,800 | $75,049 | 38.7% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 15 | 6,200 | $187,065 | $72,573 | 38.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 262 | 287 | $137,760 | $41,938 | 30.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 235 | 409 | $69,530 | $21,958 | 31.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 50 | 340 | $76,500 | $18,346 | 24.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 960 | $41,934 | $16,351 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 82 | $20,090 | $8,110 | 40.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 70 | 72 | $23,760 | $7,040 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 27 | $9,018 | $3,797 | 42.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 25 | 56 | $1,960 | $607.54 | 31.0% |
About Dr. Melina Diaz-Cardenas, M.D
Dr. Melina Diaz-Cardenas, M.D is a Infectious Disease healthcare provider based in Peachtree City, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2008. The National Provider Identifier (NPI) number assigned to this provider is 1548422843.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Melina Diaz-Cardenas, M.D has received a total of $410.83 in payments from pharmaceutical and medical device companies, with $11.88 received in 2021. These payments were reported across 26 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($410.83).
As a Medicare-enrolled provider, Diaz-Cardenas has provided services to 3,860 Medicare beneficiaries, totaling 21,353 services with total Medicare billing of $811,044. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Peachtree City, GA
- Active Since 06/27/2008
- Last Updated 02/25/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1548422843
Products in Payments
- VIBATIV (Drug) $121.59
- AVYCAZ (Drug) $76.26
- DALVANCE (Drug) $67.33
- TRIUMEQ (Drug) $41.86
- CUBICIN RF (Drug) $18.03
- PREVNAR - 13 (Biological) $14.83
- HYQVIA (Biological) $14.25
- Fluad (Biological) $13.03
- SYMTUZA (Drug) $11.88
- CUVITRU (Biological) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.